OptiNose, Inc. provided preliminary unaudited earnings guidance for the three-month period ended March 31, 2024. For the period, the company expects to report approximately $14.9 million in net revenue from sales of XHANCE; a loss from operations of approximately $8.1 million; and a net loss of approximately $14.1 million.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.13 USD | -2.59% | -4.64% | -12.40% |
05-14 | Transcript : OptiNose, Inc., Q1 2024 Earnings Call, May 14, 2024 | |
05-14 | Earnings Flash (OPTN) OPTINOSE Posts Q1 Revenue $14.9M, vs. Street Est of $13.7M | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-12.40% | 168M | |
+38.69% | 723B | |
+34.28% | 595B | |
-4.49% | 369B | |
+20.24% | 332B | |
+2.12% | 282B | |
+17.02% | 244B | |
+9.31% | 208B | |
-5.07% | 205B | |
-0.35% | 168B |
- Stock Market
- Equities
- OPTN Stock
- News OptiNose, Inc.
- OptiNose, Inc. Provides Preliminary Unaudited Earnings Guidance for the Three-Month Period Ended March 31, 2024